PURPOSE: The purpose of this study was to determine the effect of the angiogenesis inhibitor @entity10120 on blood vessels in @entity5 and wound sites. EXPERIMENTAL DESIGN: In a Phase I dose escalation study, @entity5 @entity1 were treated with daily infusions of @entity1 recombinant @entity10120 . Tumor biopsies were obtained prior to and 8 weeks after initiation of treatment. Blood vessel formation in nonneoplastic tissue was evaluated by creating a skin wound site on the arm with a punch biopsy device. The wound site was sampled with a second biopsy after a 7-day interval. This sequential biopsy procedure was performed prior to and 3 weeks after initiation of @entity10120 treatment. Vascular density, endothelial cell kinetics, and blood vessel maturity were determined in @entity5 and skin wound samples. The ultrastructure of @entity5 blood vessels was examined by electron microscopy. RESULTS: As expected, the @entity5 were of variable vascular density. Skin wounding induced a vascular granulation tissue containing a high percentage of proliferating endothelial cells. The proportion of immature blood vessels was high in @entity5 and in wound sites and low in normal skin. No statistically significant difference was detected between pretreatment and treatment samples of @entity5 and of skin wounds for any of the parameters tested. CONCLUSIONS: @entity10120 treatment was not associated with any recognizable vascular changes in @entity5 samples and did not perturb wound healing at the doses and the treatment schedule used.

Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with XXXX .

@entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'tumors'] @entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity10120 :: ('80781', 'Gene') :: ['endostatin', 'Endostatin']
@entity10120 :: (80781,Gene) :: ['endostatin']
